Immunomedics Inc. (IMMU) announced results from its Phase 1/2 study of sacituzumab govitecan on Sunday. "Sacituzumab govitecan has demonstrated encouraging activity in heavily pretreated patients with a median of five prior treatment lines for metastatic disease," said Aditya Bardia.
from RTT - Before the Bell https://ift.tt/2sxWi5W
via IFTTT
No comments:
Post a Comment